Addex Therapeutics Ltd (SWX:ADXN)

Market Cap	6.14M
Revenue (ttm)	592.36K
Net Income (ttm)	5.40M
Shares Out	98.32M
EPS (ttm)	0.05
PE Ratio	1.14
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,433,187
Average Volume	379,776
Open	0.0698
Previous Close	0.0624
Day's Range	0.0570 - 0.0698
52-Week Range	0.0500 - 0.2600
Beta	1.91
RSI	50.96
Earnings Date	Mar 24, 2025

About Addex Therapeutics

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 23
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: ADXN

Financial Performance

In 2023, Addex Therapeutics's revenue was 1.65 million, an increase of 13.99% compared to the previous year's 1.44 million. Losses were -10.56 million, -49.26% less than in 2022.